Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Bullboard Posts
Comment by malibukion Feb 01, 2019 4:22pm
86 Views
Post# 29307962

RE:RE:RE:RE:RE:January 2019 investor presentation

RE:RE:RE:RE:RE:January 2019 investor presentationI raised the issue of the positive control in NA trial loong ago and Wex said company confirmed this in his personal communication. However this issue is not mentioned anywhere explicitly. I wonder instead of saying the same thing in the video as in the update why Howard did not give real details. If there is positive control say it, if you already have preclinical efficiency data (not enzyme binding binding or toxicity) superior to marketed product, say it.

Double blind does not mean positive control is included. If not, then they can release a final update: 1067 showed a skin lightenening effect. Is it good enough? No way to comment on this without a comparison with one of the marketed products (unless 1067 makes you like albino, then you do not need such postive control). 

Chinese are doing this test which is good but I find it strange that in NA it is not confirmed officially.
Bullboard Posts